Abstract We evaluated the association of a polymorphism in TCF7L2 (RS12255372) in the WNT signaling pathway, which previously has been strongly associated with risk of Type II Diabetes, with colorectal cancer (CRC) and adenoma in the prospective Nurses' Health Study (NHS) and Health Professionals Follow-up Study (HPFS) cohorts. Hyperinsulinemia may be related to the risk of colon adenoma and cancer, therefore this variant associated with reduced insulin secretion would be predicted to be inversely associated with colorectal cancer. Overall, in the NHS and HPFS, there was suggestive evidence for an inverse association associated with homozygosity for the minor allele of RS12255372 (TCF7L2 TT) and CRC (conditional and covariate adjusted OR = 0.63, 95% CI: 0.37-1.08; P for heterogeneity 0.52 for the association in women and men). In summary, the marginal association of the TCF7L2 SNP with CRC might be due to chance, but warrants further laboratory and epidemiological investigation.
Introduction
T-cell factor (TCF)/LEF proteins facilitate the formation of multiprotein enhancer complexes to modulate the transcription of target genes. In the adenomous polyposis coli (APC)-WNT signaling pathway, interaction of T-cell factor 7 like 2 (TCF7L2, previously reported as TCF-4) with translocated b-catenin in the nucleus transiently converts TCF7L2 to a transcription factor activator, which induces the expression of target genes, including Cyclin D1 and c-MYC, in colorectal carcinogenesis [1] . Duval et al. [2, 3] characterized the genomic structure of TCF7L2/TCF-4 in colorectal cancer (CRC) cell lines. TCF7L2 has alternative exons leading to isoforms with short, medium, or long C-terminal ends; the long C-terminal ends may mediate transcriptional repression [3] . TCF7L2 frameshift mutation in MSI-H CRC leads to selective loss of TCF7L2 isoforms with CtBP-binding abilities [4] . Recently, a genome-wide analysis of 11 CRC tumor cell lines or xenografts classified TCF7L2 [5] as a cancer candidate gene (with a cancer mutation prevalence, CaMP, score of 2.8; [1 is a cancer candidate gene). Polymorphisms in TCF7L2 have been associated with disease susceptibility. Specifically, Grant et al. [6] demonstrated that a polymorphism in TCF7L2 is associated with increased risk of type II diabetes (T2D) [6] [7] [8] [9] [10] [11] [12] due to impaired beta-cell function [6, 9] . Epidemiologic studies have suggested that hyperinsulinemia may be related to the risk of colon adenoma and cancer [13] [14] [15] [16] , therefore, this variant associated with reduced insulin secretion [6] would be predicted to be inversely associated with colorectal cancer. Given its relevance to the etiology of colorectal cancer, we evaluated the main effect of the TCF7L2 (RS12255372) polymorphism with colorectal cancer and adenoma, and effect modification by family history and body mass index (BMI) in the prospective Nurses' Health Study (NHS) and Health Professionals Follow-up Study (HPFS) cohorts.
Methods

Study population
The NHS began in 1976 when 121,700 female registered nurses in the United States between the ages of 30 and 55 completed a self-administered questionnaire on their medical history and baseline health-related exposures. Subsequently, these participants have completed a mailed, self-administered questionnaire biennially to update information on their lifestyle, medical history, and diet (every 2-4 years).
Between 1989 and 1990, 32,826 women between the ages of 43 and 69, have provided blood samples. Upon receipt, samples were immediately centrifuged and aliquoted into plasma, red blood cells, and buffy coat fractions for storage in liquid nitrogen. After blood collection through June 2000, 197 incident cases of colorectal cancer were confirmed through medical records or death reports, of which 190 cases were successfully genotyped. Controls were randomly selected from women who were alive and free of cancer at the time of case ascertainment. One control was matched to each case on year of birth and month of blood draw. As previously described [17] , cases of colorectal adenoma and controls were chosen from among women who supplied blood sample, had a sigmoidoscopy or colonoscopy (by 1998) after providing blood sample, and were free from diagnosed cancer (except nonmelanoma skin cancer), ulcerative colitis, and adenoma before endoscopy. Newly diagnosed polyps (in individuals who never had a polyp diagnosed before the date of blood draw) were reported on the 1990, 1992, 1994, 1996, or 1998 questionnaire. These polyps were confirmed to be adenomatous by review of histopathological reports and were classified by location (proximal or distal colon, or rectum), size (\1 cm, C1 cm), and histology (tubular, tubulovillous, villous, and carcinoma-in-situ (CIS)) by study investigators blinded to the exposure information. Advanced adenoma was defined as large adenomas C1 cm in size and/or tubulovillous, villous, or carcinoma-in-situ histology. Between 1989 and 1998, 557 women with colorectal adenoma were identified, and one control was selected for each case, matched on year of birth, year of blood draw, time period of recent endoscopy, indication for endoscopy, and time period of first or most recent endoscopy. One case was subsequently found to be hyperplastic and was excluded from the analysis. Thus, the total number of cases and controls analyzed in this study were 556 cases and 557 controls. Diet was assessed in 1986, 1990, 1994 , and 1996 with a semiquantitative food frequency questionnaire.
The HPFS began in 1986 when 51,529 US male dentists, optometrists, osteopaths, podiatrists, pharmacists, and veterinarians, ages 40-75 years, responded to a mailed questionnaire [18] . These men provided baseline information on age, marital status, height, weight, ancestry, medications, smoking history, medical history, physical activity, and diet. Exposure and medical history information are updated every two years. Blood samples were collected from 18,225 of the HPFS participants between 1993 and 1995. Among these men, 168 incident cases of CRC were identified between the date of blood draw and January 2002. Men who were alive and free of diagnosed cancer at the time of case ascertainment were selected as controls and were matched to cases on year of birth and month of blood draw.
Genotyping methods
Genotyping was performed at the Dana-Farber/Harvard Cancer Center High-Throughput Polymorphism Core. DNA was extracted from 50-ll buffy coat fractions diluted with 150 ll of PBS by the Qiagen QIAamp Blood Kit (Qiagen, Chatsworth, CA) spin protocol. The genotype of the TCF7L2 polymorphism was determined by measuring end-point fluorescence using the 5 0 nuclease assay (Taqman) on the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA) [19] . The primers for RS12255372 (G,T) in Intron 3 TCF7L2 were: Forward: GCTGAGCTGCCCAGGAATAT; Reverse: GCAGAGGCCTGAGTAATTATCAGAA.
Quality control was ensured by including a random 10% of the samples in the 96-well plates as duplicates. The quality control samples served as internal controls to validate the genotyping methods; there was 100% concordance of the quality control samples. Laboratory personnel were blinded to the status (case, control, or quality control) of samples.
Statistical analysis
The study population included 357 incident CRC cases and 814 matched controls as well as 556 incident adenoma cases and 557 matched controls for the analyses. The number of cases and controls for the polymorphism was slightly lower because of missing genotyping data. Genotype distributions were evaluated for agreement with Hardy-Weinberg equilibrium (HWE) by the chi-square test. We evaluated differences among cases and controls using the chi-square test for categorical variables and the paired t-test for continuous variables.
We used both conditional and unconditional logistic regression for the analyses to compute genotype odds ratios (ORs), 95% confidence intervals (CIs), allelic trend tests, and interactions. In the multivariate models, we adjusted for known risk factors for colorectal neoplasia, including family history of CRC, pack-years of smoking, postmenopausal hormone (PMH) use, BMI, physical activity, aspirin use, total energy intake, and consumption of red meat, alcohol, and folate (updated dietary variables assigned according to date of colorectal neoplasia diagnosis). For all covariates, we used updated data from the most recent questionnaire completed prior to diagnosis of cancer. Unconditional logistic analyses explicitly adjusted for matching variables, including age, history of previous endoscopy (before blood draw), year of endoscopy, (endoscopy related variables for the polyps only) and month/year of blood collection and fasting status at blood collection.
The SNP was initially examined with the codominant model, evaluating TCF7L2 as a three-level categorical variable, where the homozygous variant genotype and heterozygous genotype are compared to the homozygous wild-type referent category. p-values were obtained from the tests for linear trend of log-ORs were calculated using an ordered categorical variable by assigning scores to the genotypes: 0 (no variant allele), 1 (carrying one variant allele), and 2 (carrying two variant alleles). Similar results were obtained with two-degree of freedom likelihood ratio test (2-df LRT) comparing models with and without the genotype variable.
We also used the dominant model, comparing variant carriers with the referent homozygous wild type. The risk for advanced and small adenoma was evaluated by polytomous logistic regression with an ordinal outcome variable that was modeled as a three-level categorical variable: advanced adenoma, small adenoma, and controls. Effect modification by covariates, family history, and BMI was tested with p-values obtained from the LRT comparing models with and without the interaction term between genotype and covariate. All p-values reported were twosided.
Results
Cancer
Details of this study population have been previously reported [17] . Briefly, there were 367 incident cases of CRC and 852 controls. The mean age of cases and their matched controls was 68 years. As expected, family history was more common in the cases, whereas aspirin use, multivitamin use, and being a never smoker was more common among controls.
Adenoma
Details of this study population have been previously reported [18] . The mean age of cases and their matched controls was 62.3 years. Family history of CRC, smoking [25 pack-years, BMI [ 30 kg/m 2 , and consumption more than one serving of red meat/day were associated with an increased risk of colorectal adenoma. In addition, cases were less likely than controls to be current users of PMHs or to take multivitamins and aspirin (\7 aspirin tablets/ week). A sub-analysis of distal-only adenoma did not reveal a point estimate that varied (point estimate varied less than 10%) from the overall main effect of the SNP.
TCF7L2 polymorphism
The TCF7L2 T-allele frequency ranged from 28 to 30% and the genotype distribution was in agreement with HWE (Table 1, Footnote). Overall, there was a marginal inverse association with the minor allele of RS12255372 (TCF7L2 TT) and CRC (conditional and covariate adjusted OR = 0.63, 95% CI: 0.37-1.08; P for heterogeneity 0.52 for the association in women and men, Table 1 ). The TCF7L2 polymorphism was not associated with risk of small (multivariate OR = 0.95 (95% CI: 0.74-1.18)) or advanced (multivariate OR = 1.01 (95% CI: 0.78-1.32)) colorectal adenomas (p-value = 0.82 for two-degree of freedom LRT, data not shown). The association of TCF7L2 was not statistically significant in a combined analysis of colorectal cancer and colorectal adenoma (Mantel-Hanzel p-value = 0.23, data not shown). Excluding rectal cancers and rectal adenomas, the association of the TCF7L2 variant and colon cancer and colon adenoma (GT: multivariate OR = 1.11 (95% CI: 0.80-1.54); TT: multivariate OR = 0.76 (95% CI: 0.41-1.40)) was not different from the overall association observed for colorectal cancer and adenoma (data not shown).
Furthermore, we observed no evidence of effect modification between the TCF7L2 SNP and covariates, such as family history (p-interaction = 0.45, Table 2 ) and BMI (p-interaction = 0.27, Table 2 ).
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Discussion APC is the gatekeeper tumor suppressor gene associated with CRC. High-penetrance mutations in the APC pathway are a hallmark of familial CRC (familial adenomatus polyposis or FAP). In this pathway, activated Wnt signaling leads to the accumulation of nuclear b-catenin. The cytoplasmic level of b-catenin is regulated by ubiquitin-mediated proteolysis after it is targeted for phosphorylation by glycogen synthase kinase 3b (GSK-3b). The phosphorylation of b-catenin by GSK-3b occurs in the context of a structural complex that includes Axin and APC [20] . GSK3b activity is inhibited in the presence of a Wnt signal [21] . Interaction of excess translocated b-catenin in the nucleus with TCF7L2 upregulates expression of specific target genes, including cyclin D1, c-myc [22, 23] and GLP-1 [24] . In this study, we observed a marginal inverse association between the TCF7L2 polymorphism and risk of CRC, but not adenoma. Evaluating the gene-environment association of the SNP with family history and BMI did not reveal a significant interaction. However, these findings are limited by the sample size and consequently may be diluted by using a dominant genetic model.
Several recent publications, including genome-wide association studies [25] [26] [27] [28] , have reported an increased risk of T2D among T-allele carriers. Grant et al. [6] identified DG10S478 located in intron 3-exon 4 of the TCF7L2 gene on chromosome 10q25.2 (in a well-defined LD block of 92.1 kb based on CEU HapMap v16; GenBank NM 030756) that had an r 2 of 0.95 with the rs12255372 SNP [7] . The authors suggest that the TCF7L2 variants increase T2D risk by altering proglucagon gene expression [7] in enteroendrocrine cells [24] via the WNT signaling pathway [29] . Saxena et al. [10] stated that the novel genes identified for type 2 diabetes genes act through reduced insulin secretion. Florez et al. [8] reported that individuals with the TT genotype have decreased insulin secretion [6] . The reduced insulin secretion may be due to decreased expression of proglucagon and glucagons like peptide-1 [24] . Zhang et al. [9] reported an increased risk for T2D for the TT genotype in the NHS (687 T2D, 1051 controls) with an OR of 1.86 (95% CI: 1.30-2.67) and in the HPFS (886 T2D, 896 controls) with an OR of 2.15 (95% CI: 1.48-3.13) [8] . A recent meta-analysis of 28 publications of TCF7L2 rs7903146, in LD with rs12255372, reported a pooled OR of 1.46 (95% CI: 1.42-1.51) for the minor allele [30] . A study of breast cancer risk among 592 German families [31] and 735 controls reported a modest association with increased risk (OR = 1.19 (95% CI: 1.01-1.42)) for the rs12255372 T-allele.
Hyperinsulinemia has been examined in relation to risk of colon cancer in several epidemiologic studies [13] [14] [15] [16] . In the NHS, high C-peptide, a marker of insulin secretion, has been previously associated with a marginal increase in CRC risk [16] . The authors found that women in the top quartile of C-peptide had a borderline-increased multivariate risk of colon cancer compared to women in the lowest quartile, also controlling for BMI and activity.
The TCF7L2 polymorphism is located in interspersed repeat elements, 41 kb upstream and 9 kb downstream of alternatively spliced exon 4 [6] . A limitation of this analysis is that the functional relevance of this SNP is unknown. The sample size for colorectal cancer and adenoma in women is larger than most published studies with prospective data, however, we do not have data on the HPFS incident adenoma cases and controls at this time. In summary, the marginal inverse association of the TCF7L2 TT variant, with CRC may be due to chance, but warrants further laboratory and epidemiological investigation.
